Stock Traders Buy High Volume of Boston Scientific Call Options (BSX)

Boston Scientific Corporation (NYSE:BSX) saw unusually large options trading activity on Tuesday. Stock traders purchased 5,848 call options on the company. This represents an increase of 1,042% compared to the average volume of 512 call options.

Shares of Boston Scientific (BSX) opened at $26.15 on Friday. Boston Scientific has a fifty-two week low of $20.03 and a fifty-two week high of $29.93. The firm has a market cap of $35,910.00, a price-to-earnings ratio of 21.54, a PEG ratio of 2.03 and a beta of 0.99. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.31. Boston Scientific had a net margin of 9.55% and a return on equity of 23.60%. The business had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same period last year, the business earned $0.27 EPS. The company’s revenue was up 5.6% on a year-over-year basis. sell-side analysts anticipate that Boston Scientific will post 1.25 earnings per share for the current fiscal year.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $26.66, for a total transaction of $413,230.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Valley Gold Master Fund L. Sun bought 408,006 shares of Boston Scientific stock in a transaction on Tuesday, November 28th. The shares were acquired at an average price of $0.45 per share, for a total transaction of $183,602.70. Over the last quarter, insiders have sold 414,698 shares of company stock worth $12,013,153. 0.74% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Steward Partners Investment Advisory LLC purchased a new position in shares of Boston Scientific in the 3rd quarter valued at $139,000. Salem Investment Counselors Inc. grew its position in shares of Boston Scientific by 7.6% in the 3rd quarter. Salem Investment Counselors Inc. now owns 125,175 shares of the medical equipment provider’s stock valued at $3,683,000 after buying an additional 8,802 shares during the last quarter. Iguana Healthcare Management LLC grew its position in shares of Boston Scientific by 127.3% in the 3rd quarter. Iguana Healthcare Management LLC now owns 125,000 shares of the medical equipment provider’s stock valued at $3,646,000 after buying an additional 70,000 shares during the last quarter. Moors & Cabot Inc. grew its position in shares of Boston Scientific by 3.7% in the 3rd quarter. Moors & Cabot Inc. now owns 49,975 shares of the medical equipment provider’s stock valued at $1,468,000 after buying an additional 1,800 shares during the last quarter. Finally, IFM Investors Pty Ltd grew its position in shares of Boston Scientific by 5.5% in the 3rd quarter. IFM Investors Pty Ltd now owns 39,091 shares of the medical equipment provider’s stock valued at $1,140,000 after buying an additional 2,038 shares during the last quarter. 90.55% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on BSX shares. Oppenheimer reiterated a “hold” rating on shares of Boston Scientific in a report on Wednesday, August 9th. BidaskClub upgraded shares of Boston Scientific from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Royal Bank Of Canada reiterated a “buy” rating and set a $31.00 target price on shares of Boston Scientific in a report on Friday, September 1st. Jefferies Group reiterated a “hold” rating on shares of Boston Scientific in a report on Thursday, September 7th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a report on Monday, September 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $30.61.

WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/03/stock-traders-buy-high-volume-of-boston-scientific-call-options-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

What are top analysts saying about Boston Scientific Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit